Evidence map›Paper›PMID 21872977›Full record

ArticleAmerican journal of kidney diseases : the official journal of the National Kidney Foundation2011

Venous thromboembolism in patients with reduced estimated GFR: a population-based perspective.

Amisha M Parikh, Frederick A Spencer, Darleen Lessard, Catherine Emery, Ana Baylin, Crystal Linkletter, Robert J Goldberg

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in American journal of kidney diseases : the official journal of the National Kidney Foundation, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02719418 (Study of the Bioaccumulation of Tinzaparin in Renally Impaired Patients When Given at Prophylactic Doses), which is not on this map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02719418 completednot on this mapstarted 2016, after this paper: background citation

Study of the Bioaccumulation of Tinzaparin in Renally Impaired Patients When Given at Prophylactic Doses

TypeobservationalSponsorMaisonneuve-Rosemont HospitalRan2016 to 2018Enrolled28ConditionsRenal Insufficiency, Chronic, Deep Venous Thrombosis, Protection AgainstArmsTinzaparin
3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Amisha M ParikhDepartment of Community Health, Warren Alpert Medical School, Brown University, Providence, RI, USA.
Frederick A Spencer
Darleen Lessard
Catherine Emery
Ana Baylin
Crystal Linkletter
Robert J Goldberg
University of Massachusetts Chan Medical School · USBrown University · US

Funding

UNIVERSITY OF MASSACHUSETTS CENTER FOR CLINICAL AND TRANSLATIONAL SCIENCEUL1RR031982 · NCRR · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI SULLIVAN, JOHN LEWIS · 2010 to 2011
$6.8M
The Worcester Venous Thromboembolism StudyR01HL070283 · NHLBI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI GOLDBERG, ROBERT JOEL, SPENCER, FREDERICK A · 2003 to 2011
$5.6M
NCRR NIH HHS UL1 RR031982NHLBI NIH HHS R01 HL070283NHLBI NIH HHS R01-HL70283
6 · The paper itself

Abstract

backgroundAn increased frequency of venous thromboembolism (VTE) has been shown in patients with decreased kidney function measured by decreased estimated glomerular filtration rate (eGFR). However, present practices with respect to VTE prevention and management in patients with decreased eGFR in general population settings are uncertain. STUDY

designObservational study. SETTING &

participantsCommunity investigation of 1,509 metropolitan Worcester, MA, residents with a validated VTE in 1999, 2001, and 2003 with further follow-up for up to 3 years. PREDICTOR: Patients with VTE classified further according to eGFR on presentation: <30, 30-59, 60-89, or ≥90 mL/min/1.73 m(2) (reference group). OUTCOMES: Recurrent VTE, major bleeding episodes, and all-cause mortality. MEASUREMENTS: Demographic and clinical characteristics, treatment practices, and study outcomes were extracted from patients' hospital and outpatient medical records; eGFR was estimated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.

resultsPatients with VTE with eGFR <30 mL/min/1.73 m(2) were at increased risk of recurrent VTE (HR, 1.83; 95% CI, 1.03-3.25), major bleeding episodes (HR, 2.30; 95% CI, 1.28-4.16), and all-cause mortality (HR, 1.70; 95% CI, 1.12-2.57) during a 3-year follow-up. Patients with decreased eGFR also presented with more comorbid conditions and were less likely to be discharged on any form of anticoagulant therapy (72.6%, 81.0%, 82.1%, and 87.3% for eGFR <30, 30-59, 60-89, and ≥90 mL/min/1.73 m(2), respectively; P < 0.001). LIMITATIONS: Decreased eGFR status is presumed based on creatinine values on clinical presentation. The impact of drug dosage, timing, type of anticoagulant therapy, and medication adherence on study outcomes could not be evaluated.

conclusionsSevere decreases in eGFR are associated with increased risk of long-term recurrent VTE, bleeding, and total mortality in patients with VTE. A greater frequency of serious comorbid conditions, difficulties implementing available management strategies, and suboptimal VTE prophylaxis during hospital admissions likely contributed to our findings.

Indexed as

Glomerular Filtration RateAgedFemaleHumansMaleMiddle AgedRetrospective StudiesVenous Thromboembolism

Identifiers

PMID21872977
PMCPMC3204356
OpenAlexW2033846924

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.